

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 March 2023 (30.03.2023)



(10) International Publication Number
WO 2023/045995 A1

(51) International Patent Classification:

A61K 47/54 (2017.01) *C12N 15/113* (2010.01)
C07H 5/06 (2006.01) *A61P 1/16* (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2022/120422

(22) International Filing Date:

22 September 2022 (22.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/119733

23 September 2021 (23.09.2021) CN

(71) Applicant: SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. [CN/CN]; Room 236, Building 3, 690 Bi-bo Road, Pudong New District, Shanghai 201203 (CN).

(72) Inventors: SHU, Dongxu; Room 201, No.24, Lane 535, Qingnian Road, Qiutai Town, Yinzhou District, Ningbo, Zhejiang 315100 (CN). SHAO, Pengcheng Patrick; 631 Addison Way, Warrington Township, Pennsylvania 018976 (US).

(74) Agent: UNITALEN ATTORNEYS AT LAW CO., LTD.; 7th Floor, Scitech Place, No.22, Jian Guo Men Wai Ave. Chao Yang District, Beijing 100004 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents

(57) Abstract: Multivalent ligand clusters, having a diamine scaffold, for targeted delivery of pharmaceutical agents conjugated thereto are described. A multivalent ligand cluster may comprise one or more N-acetylgalactosamine (GalNAc) targeting ligands. A multivalent ligand cluster may be conjugated to one or more small interfering ribonucleic acids (siRNAs), with siRNA being an example of a pharmaceutical agent. Compositions comprising a multivalent ligand cluster, and methods of making a multivalent ligand cluster, are also described.

WO 2023/045995 A1